Newsfeeds - Spark Newswire

3 minute read

AzurRx BioPharma Announces Phase 2 MS1819 Combination Therapy Trial Met Primary And Secondary Outcome Measure Endpoints

Today, 6:07 AM

MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints Study data indicates clinically meaningful improvement in coefficient of fat MS1819 and PERT combination therapy achieves primary and secondary outcome measure endpoints

AZRX

2 minute read

12 Health Care Stocks Moving In Tuesday’s After-Market Session

By Benzinga Insights

Today, 6:07 AM

Gainers

ALT

20 minute read

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 6:07 AM

Tuesday morning, 282 companies set new 52-week lows.

AAOI

2 minute read

News

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

By Benzinga Newsdesk

Today, 6:07 AM

AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced

AZRX

2 minute read

AzurRx BioPharma Adds New Clinical Trial Sites In Ukraine For Phase 2 RESERVOIR Clinical Trial Of Niclosamide For The Treatment Of COVID-19 Gastrointestinal Infections

By Bill Haddad

Today, 6:07 AM

AzurRx BioPharma, Inc. ("AzurRx" or the "Company") (NASDAQ:AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI)

AZRX

2 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 6:07 AM

AMTI

3 minute read

20 Stocks Moving in Monday’s Pre-Market Session

By Lisa Levin

Today, 6:07 AM

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT) shares rose 55.8% to $2.82 in pre-market trading after dropping over 10% on Friday. The company recently reported a wider loss for its second quarter.

ACER

1 minute read

HC Wainwright & Co. Maintains Buy on AzurRx BioPharma, Lowers Price Target to $2

By Benzinga Newsdesk

Today, 6:07 AM

HC Wainwright & Co. analyst Yi Chen maintains AzurRx BioPharma (NASDAQ:AZRX) with a Buy and lowers the price target from $2.5 to $2.

AZRX

7 minute read

75 Biggest Movers From Friday

By Lisa Levin

Today, 6:07 AM

Gainers The New Home Company Inc. (NYSE: NWHM) jumped 82.9% to settle at $8.89 on Friday after the company agreed to be acquired by funds managed by affiliates of Apollo Global Management for $9 per share in all-cash transaction.

AACG

5 minute read

50 Stocks Moving In Friday’s Mid-Day Session

By Lisa Levin

Today, 6:07 AM

Gainers Xenetic Biosciences Inc (NASDAQ: XBIO) shares jumped 111.3% to $3.9299 on abnormally-high volume.

ACOR